Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Company codeMEDP
Company nameMedpace Holdings Inc
IPO dateAug 11, 2016
Founded at2014
CEODr. August J. Troendle, M.D.
Number of employees5900
Security typeOrdinary Share
Fiscal year-endAug 11
Address5375 Medpace Way
CityCINCINNATI
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code45227-1543
Phone15135799911
Websitehttps://investor.medpace.com/
Company codeMEDP
IPO dateAug 11, 2016
Founded at2014
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data